Plasma‐soluble urokinase plasminogen activator receptor (suPAR) levels in Behçet's disease and correlation with disease activity

• Published in: International journal of rheumatic diseases Vol. 21; no. 4; pp. 866 - 870
• Main Authors: Saylam Kurtipek, Gulcan, Kesli, Recep, Tuncez Akyurek, Fatma, Akyurek, Fikret, Ataseven, Arzu, Terzi, Yuksel
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.04.2018
• Subjects: Adult; Aged; Behcet Syndrome - blood; Behcet Syndrome - diagnosis; Behcet's syndrome; Behçet's disease; Biomarkers; Biomarkers - blood; C-Reactive Protein - analysis; Case-Control Studies; C‐reactive protein; Enzyme-Linked Immunosorbent Assay; Female; Humans; inflammation; Inflammation Mediators - blood; Male; Middle Aged; Plasma; Plasma levels; Predictive Value of Tests; Prognosis; Receptors, Urokinase Plasminogen Activator - blood; Severity of Illness Index; Statistical analysis; suPAR; U-Plasminogen activator; Up-Regulation; Vein & artery diseases; Behçet's disease; C-reactive protein; inflammation; suPAR
• ISSN: 1756-1841; 1756-185X
• DOI: 10.1111/1756-185X.12873

Background Soluble urokinase plasminogen activator receptor (suPAR), a new biomarker, is a soluble form of membrane‐bound receptors secreted from different immune cells. The aim of the present study is to determine plasma suPAR levels in Behçet's disease and their correlation with disease activity. Methods Thirty Behçet's disease patients determined according to the International Study Group criteria for Behçet's disease diagnosis and 41 healthy subjects were included in the present study. Micro‐enzyme‐linked immunosorbent assay was employed to obtain quantitative data. Data of both groups were statistically analyzed. Results The comparison of C‐reactive protein and suPAR plasma levels of the control and Behçet's disease group revealed statistically significant differences (respectively, P = 0.003 < 0.05 and P = 0.020 < 0.05). However, plasma suPAR levels related with disease activity revealed no statistically significant differences (P > 0.05). Conclusion The present study is the first study analyzing suPAR levels in Behçet's disease patients and their correlation with disease activity. However, further prospective studies with larger patient series using suPAR as a new plasma biomarker are required to diagnose and monitor Behcet's disease and to support the findings of the present study.